ABBV Stock Price Today (September 2026) — AbbVie Inc. Analysis & Key Metrics 2026-09-03
AbbVie Inc. (ABBV) is trading at $260.21, down 0.58% today (as of September 2026). The stock continues to show sustained strength above key moving averages, attracting attention from investors looking for Healthcare growth opportunities.
- According to consensus analyst estimates, the 1-year price target is $276.59 (6.3% upside).
- Volatility remains elevated (20.07% annualized), implying wide price swings for short-term traders.
- The fundamental picture, based on the latest financial filings, is nuanced: solid revenue growth (10.20% YoY) alongside significant competitive pressures.
ABBV Stock Analysis: Key Metrics & Valuation (September 2026)
Concise, actionable data for investors
AbbVie Inc. - Historical Price & Volume
Market Cap
Enterprise Value: $515.83B
P/E Ratio
Forward P/E: 15.75
Revenue Growth
Year over Year
Analyst Target
+6.3% upside potential
Key Investor Questions About ABBV
What investors need to know before buying
Based on current market data, ABBV presents a neutral technical setup with mixed signals fundamentals.
- Technicals say: Neutral (RSI 55.52)
- Fundamentals say: Mixed signals (nuanced financial profile)
ABBV's growth trajectory depends on its ability to expand within the Drug Manufacturers - General sector while managing margin pressures.
- Future growth will depend on performance in core Drug Manufacturers - General operations.
- The ability to manage competitive pressures will be crucial for sustained growth.
The primary risks for ABBV investors include debt exposure and competitive dynamics in the Drug Manufacturers - General industry.
- $70.88B in debt could be a headwind in a high-rate environment.
- Fierce competition from established players in Drug Manufacturers - General.
52-Week Trading Range
Over the past year, ABBV stock traded between $190.75 and $267.47—recovering meaningfully from lows and currently near the higher end. Big swings are likely unless a major catalyst emerges.
Volatility & Risk Profile
With 20.07% annualized volatility and β=0.33, the stock exhibits low sensitivity to market moves—making ABBV suitable for investors comfortable with active risk management.
Institutional & Insider Ownership
High institutional backing, but elevated short interest signals a potential battleground stock.
Analyst Sentiment & Price Targets
Latest News & Headlines
Recent headlines and coverage
AbbVie (ABBV)’s Blood Cancer Success Adds Weight to its Pipeline Story
AbbVie Inc. (NYSE:ABBV)’s experimental blood-cancer therapy etentamig delivered positive results in a late-stage trial for patients with relapsed or refractory multiple myeloma, meeting the trial’s main objectives. The drug produced an objective response rate of 74%, compared with 45.7% for standard treatments selected by investigators. More importantly, etentamig reduced the risk of disease progression or […]
AbbVie's Etentamig Delivers 74% Response Rate in Pivotal Cancer Trial
Etentamig beat standard treatment by 28.3 percentage points and met the Phase 3 study's progression-free-survival goal.
J&J Gains as AbbVie Posts 74% Myeloma Response
Etentamig could expand treatment after CAR-T therapy without immediately displacing J&J's fast-growing Carvykti franchise.
The "Untouchable" List: Stocks That Short Sellers Won't Dare Bet Against
Why Short Sellers Are Running Scared from These Stocks
Top Analyst Reports for Amazon, AbbVie & Alibaba
Amazon, AbbVie and Alibaba face contrasting growth drivers and challenges, from AI investment and drug launches to costly spending cycles.
Sector Update: Healthcare Stocks Edge Higher Late Afternoon
Healthcare stocks were slightly higher late Thursday afternoon, with the NYSE Healthcare Index incre
AbbVie Touts Positive Data For Multiple Myeloma Drug
AbbVie Inc. (NYSE:ABBV) on Thursday reported topline outcomes from its Phase 3 CERVINO trial evaluating etentamig, an investigational treatment for relapsed or refractory multiple myeloma. The study demonstrated that the drug outperformed standard therapies, meeting its primary goals for objective response rate and progression-free survival. Read Also: Merck, AbbVie Hit With Congressional Probe Over China Drug Trials: Report Efficacy And Trial Metrics At a median follow-up of 11.4 months, resear
Is Merck Stock Pricing In A Post-Keytruda Future Too Soon?
Merck’s stock is the top performer in its group, but its profitability sits at the very bottom of the pack, forcing a hard question on investors.
ABBV Stock Has Returned $62 Billion To Shareholders. Should You Care?
A pharma giant delivered substantial cash returns to shareholders while outperforming the broader market. Here is a breakdown of AbbVie's cash-return capacity, and the key commercial metric supporting its durability.
Pfizer (PFE) Up 12.4% Since Last Earnings Report: Can It Continue?
Pfizer (PFE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Explore More Analysis for ABBV
Additional research, tools, and technical breakdowns
Stock Analyzer Report
Deep-dive automated research and stock rating report.
DCF Fair Value Calculator
Discounted cash flow model and intrinsic value projection.
AI Price Predictions
Multi-scenario price predictions and consensus targets.
Insider Activity Tracker
Track buying/selling behavior of corporate insiders.
Earnings Calendar
Track upcoming and historical corporate earnings reports.
Market Insights & Research
Read the latest analysis articles and expert research.
Frequently Asked Questions
Common investor questions about AbbVie Inc.
AbbVie Inc. (ABBV) is currently trading at $260.21. The RSI (14-day) is at 55.5, indicating neutral territory. Wall Street analysts have a consensus "buy" recommendation. The mean analyst price target of $276.59 implies 6.3% upside from current levels. Volatility is moderate at 20.1% annualized, meaning price movements are relatively contained. Investors should consider their risk tolerance, investment horizon, and portfolio diversification before making a decision.
Based on current valuation metrics for AbbVie Inc. (ABBV): The trailing P/E ratio is 73.30, which is above the market average, indicating investors are pricing in higher growth expectations. The forward P/E is 15.75, lower than the trailing P/E, suggesting analysts expect earnings improvement. The PEG ratio is 0.42, below 1.0, which generally indicates the stock is undervalued relative to its growth rate. Price-to-Book is -76.34. Price-to-Sales is 7.14. Valuation should be compared to Drug Manufacturers - General industry peers for context, as different sectors trade at different multiples.
Based on 29 analysts covering ABBV, the consensus price target is $276.59. This represents a 6.3% upside from the current price of $260.21. The range spans from a low target of $200.00 to a high target of $328.00, reflecting varying levels of optimism among analysts. The consensus recommendation is "buy". Note: Analyst price targets are forward-looking estimates and not guarantees of future performance.
Yes, AbbVie Inc. (ABBV) pays a dividend with a current yield of approximately 2.66%. The annualized dividend rate is $6.83 per share. The payout ratio is 190.4%, which exceeds 100%—this means the company is paying out more than it earns, which may not be sustainable long-term. The most recent ex-dividend date was 2026-07-15T00:00:00.000Z.
Key risks for AbbVie Inc. (ABBV) investors include: 1. Unsustainable dividend payout ratio (190%) could lead to a dividend cut. 2. Broader market and macroeconomic risks (interest rates, inflation, geopolitical events). 3. Drug Manufacturers - General sector-specific competitive pressures. Investors should diversify and consider their risk tolerance before investing.
Here is AbbVie Inc.'s (ABBV) current debt and financial health profile: Total debt stands at $70.88B. The current ratio is 0.81, which is below 1.0 and may indicate short-term liquidity concerns. The quick ratio is 0.49. The company holds $6.57B in cash and equivalents. Free cash flow is positive at $16.87B, providing a cushion for debt servicing and shareholder returns.